185 0 Kommentare Chr. Hansen Holding A/S Interim Report Q3 2022/23

July 6, 2023 – Company announcement no. 7

Strong execution by the organization drives solid Q3 results
Statement by CEO Mauricio Graber: “The solid results for Q3 prove the strength of the Chr. Hansen organization which continues to deliver first-class products and innovative solutions to customers around the world, while the process with Novozymes to complete the proposed merger is progressing. Organic growth came in at 9%, driven mainly by pricing initiatives. EBIT b.s.i. increased by 9% despite higher input costs and a less favorable product mix, leading to an EBIT margin b.s.i. of 27.5%. In light of the solid performance for the first nine months of the financial year, we adjust our outlook for 2022/23 for organic growth to 9-11%, while maintaining the outlook for the EBIT margin b.s.i. of 26-27%. The outlook for the free cash flow b.a.s.i. is adjusted to EUR 200-230 million.
Together with Novozymes, we continue the regulatory approval process with closing expected in the fourth quarter of the 2023 calendar year or the first quarter of the 2024 calendar year.”

Q3 2022/23 highlights

Revenue amounted to EUR 335 million, up 5% from EUR 318 million in Q3 2021/22. Year-to-date revenue amounted to EUR 982 million, up 10% from last year.
Organic growth was 9%, driven by pricing. Organic growth was 10% in Food Cultures & Enzymes and 7% in Health & Nutrition. The Lighthouses delivered 15% organic growth combined in Q3, while the core businesses delivered 8% organic growth. Year-to-date Group organic growth was 10%. The Lighthouses delivered 19% organic growth for the year to date, while the core businesses delivered 9% organic growth.
EBIT b.s.i. amounted to EUR 92 million, up 9% from EUR 85 million in Q3 2021/22. The increase was driven by a positive contribution from pricing initiatives, volume growth, and stable operating expenses which was partly offset by a negative impact from higher input costs and exchange rates. Year-to-date EBIT b.s.i. amounted to EUR 260 million, up 11% from last year.
The EBIT margin b.s.i. was 27.5%, up from 26.7% in Q3 2021/22. The increase was driven by the strong sales development and scalability effects which were partly offset by a negative impact from higher input costs, a change in product mix, and exchange rates. The year-to-date EBIT margin b.s.i. was 26.4%, compared to 26.3% last year.
Free cash flow b.a.s.i. amounted to EUR 133 million for the year to date, up 15% from EUR 116 million last year, due to a higher cash flow from operating activities and a positive impact from taxes paid.